Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
What factors would determine which currently approved agent to use as a first line treatment for a stage IV ROS-1 fusion patient with the approval of repotrectinib?
Related Questions
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
In patients with stage III NSCLC who experience locoregional recurrence after neoadjuvant chemoimmunotherapy, surgery, and maintenance immunotherapy, and are treated with definitive chemoradiation at recurrence—what is the optimal systemic therapy strategy post-chemoradiation?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
What high-risk features for stage I NSCLC would lead you to consider adjuvant osimertinib?
In patients with resected stage II-III NSCLC, who completed adjuvant carboplatin and pemetrexed and are PD-L1 high, which immunotherapy would you offer?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
Would you offer a RET inhibitor to a patient with de novo metastatic, RET V706M mutant squamous cell lung cancer?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
